With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
A look back at 2016's recurring bills reveals a stark financial truth: small, consistent savings on expenses like cable, cell plans, or insurance, when invested, could have yielded a significant nest egg by today.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
While passive index funds mirror the broader market, selecting individual winners can dramatically boost returns. Citi Trends (NASDAQ: CTRN) shares have surged 77% over the past year, far exceeding the market's 14% gain, as investors bet on a potential revival despite ongoing profitability challenges.
Shares of specialty insurer Kinsale Capital have tumbled over 11% in six months, starkly underperforming the surging S&P 500. As investors digest its latest earnings, the debate intensifies: Is this a rare chance to buy a high-growth company at a discount, or a signal of deeper challenges ahead?
A major advisory firm's complete exit from a short-term Treasury ETF is sparking debate on whether institutional investors are moving idle cash into higher-growth opportunities.
CECO Environmental Corp. (NASDAQ: CECO) has surged in recent months, nearing its yearly high. With the mid-cap clean tech firm now trading near fair value, we analyze whether investors have missed the bargain window or if strategic entry points remain.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
U.S. stock futures retreated Monday as investors parsed a mixed bag of global manufacturing data, raising fresh questions about the durability of corporate earnings against a backdrop of cooling factory activity in key European economies.
Global logistics firm GXO will close its Romeoville, Illinois plant this April, citing evolving business needs. The move, announced under state WARN Act requirements, eliminates 32 positions, though the company says affected workers may apply for roles at other sites.
While small-cap stocks have broadly underperformed, recent insider buying activity points to potential value in select global companies. We examine three firms where leadership is putting their own capital to work.
A sharp supply crunch is driving contract prices for mainstream DRAM memory chips up by as much as 95% quarter-on-quarter in early 2025, according to a revised forecast from market analyst TrendForce.
Global insurer Chubb Limited prepares to release its fourth-quarter financial results after Tuesday's market close, with investors weighing solid peer performances against broader sector headwinds.
Japan's financial giant Nomura Holdings is scaling back risk at its digital asset unit following Q3 losses, a strategic pullback that mirrors wider pain across the crypto treasury sector as Bitcoin struggles to hold key levels.
Russian forces have reportedly seized the settlement of Prydorozhnie in southeastern Ukraine's Zaporizhzhia region, according to a defense ministry statement. The claim, yet to be independently verified, marks the latest in a series of incremental territorial gains.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
A new forecast reveals streaming platforms are set to increase sports rights spending by 7% in 2026, with Amazon's Prime Video overtaking DAZN as the top investor, signaling a major shift in the battle for live sports dominance.
While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.
Ethereum's price has plunged 27% in five days, bringing it perilously close to the $2,000 threshold. While fear-driven selling dominates, on-chain metrics suggest the sell-off may be nearing exhaustion, potentially setting the stage for a long-term recovery.
